Clinical Trial Update: Vaccination With Peptides in Combination With Either Ipilimumab or Vemurafenib for the Treatment of Unresectable Stage III or IV Malignant Melanoma [Phase 1]

View source ↗

Summary

Phase 1 study evaluating peptide vaccination in combination with ipilimumab or vemurafenib for unresectable stage III or IV malignant melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Vemurafenib (vemurafenib)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Herlev Hospital | Conditions: Malignant Melanoma With Metastasis | Phase 1 | Status: COMPLETED